Skip to main content
BCAX logo

BCAX · Bicara Therapeutics Inc.

Track BCAX — free
$24.70 +0.12 (+0.49%)
Market Cap
$1.64B
Shares
66.17M

Bicara Therapeutics Inc. Earnings Call Transcripts

Quarterly earnings calls for Bicara Therapeutics Inc. (BCAX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-11
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Confident tone Pivotal Phase III FORTIFY-HN01 study Commercial readiness and launch preparation Colorectal cancer signal-seeking study
Diluted EPS
$-0.82
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Confident tone Clinical data and ASCO presentation Competitive landscape dynamics Leadership transition (CMO change)
Diluted EPS
$-0.93
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-30
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
Confident tone Breakthrough Therapy Designation and regulatory momentum Clinical data – durability and depth of response Interim analysis and overall survival endpoint
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Bicara Therapeutics Inc. (BCAX) Q3 2025 Earnings Call
Diluted EPS
$-0.67
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Bicara Therapeutics Inc. (BCAX) Q2 2025 Earnings Call
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Bicara Therapeutics Inc. (BCAX) Q1 2025 Earnings Call
Diluted EPS
$-0.68
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Bicara Therapeutics Inc. (BCAX) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Bicara Therapeutics Inc. (BCAX) Q3 2024 Earnings Call
Diluted EPS
$-1.60
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts CIK 2023658 CUSIP 055477103 13F (30d) 161 filings 160 filers Visit website Investor relations